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Abstract
Background: Deep brain stimulation (DBS) of the ventral intermediate nucleus (VIM) of the thalamus is effective in
medication refractory essential tremor (ET). In recent years, evidence has accumulated that the region ventral to the
VIM, the posterior subthalamic area (PSA), might be an equally or even more effective target for electrode implantation.
However, this evidence is primarily based on case series, cross-sectional observations, and retrospective data.
Methods/design: A prospective crossover pilot study investigating the effects of PSA stimulation in medication
refractory ET patients was designed. In this study, bilateral electrodes are implanted such that at least one of the
electrode contacts is located in the PSA and VIM, respectively. This implantation approach allows (1) a prospective
double-blind investigation of the effects of PSA stimulation compared to baseline, as well as (2) a crossover comparison
between VIM and PSA stimulation with respect to tremor suppression and side effect profiles.
Discussion: The results of this double-blinded, prospective study will allow a better understanding of the effects and
side effects of PSA compared to VIM-DBS in patients with ET.
Trial registration: German Clinical Trials Register: DRKS00004235. Registered on 4 July 2012.
Keywords: Deep brain stimulation (DBS), Ventral intermediate nucleus of the thalamus (VIM), Posterior subthalamic
nucleus (PSA), Essential tremor (ET), Zona incerta (Zi), Stimulation-induced side effects, Constant current stimulation,
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Background
Essential tremor (ET) is the most common movement
disorder with a prevalence of approximately 5 % in a
population of 65 years of age and older [1]. ET clinically
presents as a bilateral, largely symmetrical postural or
kinetic tremor involving hands and forearms [2] and
sometimes even the legs, the trunk, or the head and voice.
Depending on the severity of the symptoms, ET can lead
to significant impairment of activities of daily living [3]
and may reduce quality of life [4].
Medical treatment of ET is often unsatisfactory or lim-
ited by side effects in up to 50 % of patients with ET [5].
Deep brain stimulation (DBS) is an effective and safe
treatment option for pharmacologically resistant ET [6].
The target of choice hitherto has been the ventral inter-
mediate nucleus (VIM) of the thalamus (VIM-DBS) [7].
However, habituation of tremor suppression [8] and
stimulation-induced long-term side effects such as gait
ataxia [9] or stimulation-induced dysarthria [10] may
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limit the net benefit of DBS in this target area and re-
duce individual perception of quality of life.
In recent years, the posterior subthalamic area (PSA),
including the prelemniscal radiation and the zona
incerta, emerged as a potential new anatomical target to
treat ET [11–14] (for a review see Xie et al. [15]). Some
studies found a superior effect of PSA stimulation in
comparison to VIM stimulation when the same stimula-
tion parameters were used [16–18]. Few studies compared
the effect of the two target areas under the best clinical
settings: whereas Sandvik et al. found more than half of
the best clinical contacts in the PSA [19], Chang et al.
compared VIM, PSA, and simultaneous VIM and PSA
stimulation and observed no differences in the overall out-
come of tremor suppression [20]. Another retrospective,
non-randomized study reported 70 % hand tremor reduc-
tion in the VIM group and 89 % in the PSA group [21].
Few studies investigated the side effects of PSA stimula-
tion, which can mainly be stimulation-induced dysarthria,
gait ataxia, or limb paresthesia contralateral to the stimu-
lation side [22, 23].
So far, to our knowledge, no controlled prospective
studies on PSA stimulation in patients with ET with
comparison to VIM stimulation are available. To this
end, we designed a prospective, controlled pilot study in-
vestigating the outcome of PSA stimulation in ET pa-
tients. Bilateral electrodes are implanted such that VIM
and PSA can be stimulated with different contacts of the
same lead to allow a direct comparison of the two target
areas in a randomized, double-blinded crossover design.
This approach allows comparison of tremor reduction,
quality of life, and side effects during PSA stimulation
with baseline, as well as with VIM stimulation.
Study questions
Study question 1
Study question 1 asks: Does PSA stimulation reduce
tremor severity under PSA-DBS compared to baseline as
measured by the Tremor Rating Scale (TRS) [24]? Fur-
thermore, we expect an increase of general and disease-
specific quality of life postoperatively (SF-36 [25] and
Quality of life in Essential Tremor Questionnaire, QUEST
[4]) and a certain degree of stimulation-induced side ef-
fects under PSA stimulation such as dysarthria [10] or gait
ataxia [9].
Study question 2
Study question 2 asks: Does PSA stimulation reduce
tremor severity compared to VIM stimulation measured
by the TRS in a double-blinded crossover? Although the
reports comparing PSA- and VIM-DBS are partially con-
flicting, we hypothesize a superiority of PSA over VIM
stimulation with regard to tremor suppression. As de-
scribed earlier, this superiority could be eroded due to
side effects that might occur under PSA stimulation (so
that ideal stimulation parameters cannot be set due to
side effects) or due to application of more current in the
VIM, thus equalizing the effect on tremor [17]. Due to
the overall lack of studies comparing quality of life and
DBS-induced side effects between VIM- and/or PSA-
DBS, the study remains exploratory, since we were un-
able to create specific hypotheses for the occurrence of
side effects in both regions.
Methods
Study design
The study design is illustrated in Fig. 1. After baseline
evaluation, patients are implanted as described below
(see study procedure). Three months post-implantation,
patients enter a double-blinded crossover phase with
VIM- and PSA-DBS in randomized order. After 7 months
follow-up (7MFU), programming parameters are not re-
stricted until termination of the study at 12MFU.
Study procedure
Patients are screened for study participation and im-
planted with DBS systems capable of current-controlled
(mA) stimulation (Activa RC/PC, Medtronic or Vercise
System, Boston Scientific) in the VIM and PSA bilat-
erally within 6 weeks of study enrollment. Both leads are
implanted so that each lead has at least one contact in-
side the PSA, one inside the VIM, and one ”neutral con-
tact” located on the intercommissural line (ICL, line
connecting the anterior with the posterior commissure)
in between the two target areas. Between implantation
and randomization at 3MFU, this neutral contact is acti-
vated and adjusted for optimal tremor suppression with
minimal side effects. This is done to ensure that all
patients receive the same type of stimulation before
entering the randomization phase of the study.
Only if implantation criteria are fulfilled, i.e., both
leads are placed as described above and proper lead lo-
cation is confirmed via stereotactic X-ray or postopera-
tive CT scan, are patients included at 3MFU into the
double-blinded, randomized phase of the study. Patients
are randomized into two groups (group 1: VIM-DBS
followed by PSA-DBS; group 2: PSA-DBS followed by
VIM-DBS). The crossover is double-blinded (neither the
patient nor the treating neurologist knows which area is
stimulated in which period) and lasts for 4 months
(2 months on each treatment). A programming visit (PV)
is performed at the beginning of each period (at 3MFU
and 5MFU) and the best clinical stimulation parameters of
the respective contact are determined (i.e., best tremor
suppression with no or tolerable side effects). The stepwise
increase of current of the electrode contacts in the cross-
over phase yields a better understanding of the therapeutic
windows (i.e., range between effect and side effect) of the
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two target areas. Double-blinding is also maintained dur-
ing the programming visit, as adjustment of stimulation
parameters is performed by an independent investigator
(programmer) as instructed by the blinded rater. An
evaluation visit (EV) is performed after each group (EV1
at 5MFU and EV2 at 7 MFU). As the effects and side ef-
fects are known to be immediate (although not systemat-
ically investigated for VIM-DBS), a longer washout phase
between the two crossover phases is not necessary. After
the crossover phase, the contact with the best effect and
fewest side effects or more complex stimulation paradigms
(such as double monopolar or bipolar configurations) can
be freely chosen for further treatment until 12MFU.
For study question 1, the change from preoperative to
postoperative TRS during 2 months of PSA stimulation
will be analyzed. Therefore, the data will be pooled
from the EV at 5MFU and 7MFU depending on
randomization.
Patients without electrode placement according to the
implantation criteria (see above) but with electrodes bi-
laterally located in the PSA will be stimulated in the
PSA directly after implantation, evaluated at 3MFU and
12MFU, and will be excluded from the comparison be-
tween PSA and VIM. For the longitudinal PSA effect,
3MFU data from these patients will be pooled with
5MFU and 7MFU data from the randomization group,
respectively.
During the entire study the patients are treated with
current-controlled (mA) stimulation settings which
allow a better comparability of the amount of current
applied to the tissue in the crossover design. TRS will
be video-recorded for blinded, external analysis of the
primary endpoint. Patients not eligible for the study or
patients who do not give informed consent for study
participation will be treated according to our clinical
standard.
Population, screening, and recruitment
Patients with medication refractory ET will be screened
and recruited at the Department of Neurology, Cologne
University, Germany. A neurologist specialized in move-
ment disorders (LT) will assess the patients’ eligibility
for study participation.
Inclusion and exclusion criteria
The inclusion and exclusion criteria of this study are
in line with other ET-DBS studies as well as with the
recommendations of the German DBS study group,
which will help to ensure comparability [7]. Medica-
tion refractory ET is defined as at least two medical
treatment attempts with at least two different medication
groups (e.g., beta blockers, antiepileptic drugs) without a
satisfying effect (either due to insufficient effect or side
effects) for the patient.
Fig. 1 After enrollment and baseline evaluation, patients will be bilaterally implanted with DBS electrodes in the VIM and PSA. The electrodes are
placed such that one contact is located on the intercommissural line (ICL), the neighboring ventral contact in the PSA, and the neighboring
dorsal contact in the VIM. After implantation, the neutral contact on the ICL is activated until 3 months follow-up (3MFU). At 3MFU patients are
randomized into a blinded crossover phase for 4 months (gray box). Depending on randomization, patients receive stimulation in the sequence
PSA-VIM or VIM-PSA. Each phase of the crossover starts with a programming visit (PV) and ends with an evaluation visit (EV). After the blinded
crossover phase, the stimulation contacts can be freely chosen until 12MFU
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In detail, the key inclusion criteria are:
1. Confirmed diagnosis of ET according to the
Movement Disorder Society (MDS) consensus
diagnostic criteria [26]
2. Age >18 years
3. Sufficient competence in the German language
4. At least two medication attempts without
satisfactory tremor control
5. Capability to provide informed consent.
Exclusion criteria are:
1. Clinically relevant dementia that might interfere
with the study
2. Clinically relevant psychiatric disorder that might
interfere with the study
3. Surgical contraindication for bilateral DBS
4. Participation in another interventional trial
5. Brain atrophy (i.e., width of third ventricle >10 mm)
6. Preoperative and perioperative intake of
anticoagulative medication.
Outcome measures
The primary endpoint of this study is the reduction of
tremor, measured via a reduction in TRS scores, due to
PSA-DBS over 2 months compared to preoperative base-
line. The TRS is a widely used and well-accepted scale
for the clinical assessment of tremor and has been used
in most controlled ET studies. The scale was first pub-
lished in 1993 [24] and validated for ET in 2007 [27]. It
consists of three parts: (A) tremor assessment, (B) task
assessment, e.g., pouring water from one glass into an-
other, writing, drawing spirals, and (C) a questionnaire
assessing activities of daily living, e.g., eating soup with a
spoon, social distress, hygiene; the different parts reflect
the impairment due to tremor in different dimensions.
The TRS has also been used as the primary endpoint
measure in the retrospective analysis of Blomstedt et al.
[13], which is the basis of power calculation for our
study.
Secondary endpoints comprise general (SF-36 [25])
and disease-specific quality of life (QUEST [4], non-
validated German version), depression (Beck Depression
Inventory, BDI-II [28]), ataxia (International Cooperative
Ataxia Rating Scale, ICARS [29]), and the patients’ and
physicians’ subjective impressions on tremor severity
and side effects (gait and speech) measured via visual
analog scale (VAS). Stimulation-induced side effects are
determined and recorded as adverse events throughout
the study.
In addition, the amount of electric current applied dur-
ing adjusted stimulation comprises a further endpoint. In
case no difference in efficacy is seen between PSA and
VIM stimulation in the crossover phase, it is particularly
important to detect whether PSA stimulation requires less
current on average and if the side effect profile differs in
contrast to VIM stimulation. An acoustic speech sample is
collected at each visit. The samples are analyzed by a
phonetician and speech therapist as previously described
[10, 30].
Together, these instruments provide a comprehensive
assessment of subjective and objective treatment effects
beyond mere motor effect.
Sample size and power calculation
Study question 1 concerns the tremor reduction at 5/
7MFU due to PSA-DBS compared with baseline. Blomstedt
[13] measured a mean reduction in TRS from 46.2 at base-
line to 18.7 one year later in 21 patients with ET treated
with PSA-DBS, with standard deviations of 10.1 and 8.8,
respectively.
For study question 2 comparing PSA-DBS with VIM-
DBS, a power of 80 % at significance level 5 % can be
attained for a difference of 9 points on the TRS, corre-
sponding to one-third of the tremor reduction from
baseline due to PSA-DBS, with a sample size of n = 12
(calculated using the program PS version 3.0.43). A correl-
ation coefficient of 0.5 between the two post-stimulation
values is assumed.
For study question 1, testing for tremor reduction from
baseline under PSA stimulation, assuming the same values
of significance level and power, using the paired t test, the
sample size was calculated as n = 4. Alternatively, with the
previously determined sample size of n = 12 a tremor re-
duction of 9.7 points could be detected. This calculation
involved assuming that the baseline and post-stimulation
values of a particular patient are positively correlated, with
a correlation coefficient of 0.5.
In case of missing data on the tremor score due to loss
to follow-up or withdrawal of consent, the patient does
not contribute to the analysis. A 20 % safety margin was
allowed for such cases, giving a target recruitment of 15
patients.
Statistical analysis
For study question 1, the reduction of tremor due to
PSA-DBS is calculated by subtracting the TRS score at
baseline from the score obtained after the 2 months of
continuous PSA stimulation (either 5MFU or 7MFU, de-
pending on randomization).
As a secondary endpoint, the TRS score at 12 MFU
under PSA stimulation is analyzed as a long-term par-
ameter. Only some patients are stimulated in the PSA
between 7MFU and 12MFU, since some patients might
have chosen VIM stimulation after the randomization
phase. Accordingly, a comparison between VIM and PSA
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stimulation at 12MFU might be possible (according to the
group size).
For all other (secondary) endpoints evaluated for PSA-
DBS, the difference between the score at 5/7MFU and
the score at baseline is calculated.
For study question 2, the difference in tremor scores
between PSA and VIM stimulation in each individual
patient is calculated as the difference between TRS at
5MFU and 7MFU.
For all other (secondary) endpoints compared between
PSA and VIM, the scores at 5MFU are compared with
those at 7MFU, according to randomization group.
For study question 1, the mean reduction in tremor
(TRS) due to PSA-DBS with its standard error and 95 %
confidence interval is computed. The individual baseline
and after-treatment values are tested against ”no reduc-
tion” using a paired t test. Similarly for SF-36, QUEST,
and BDI-II, the mean change from baseline together with
the corresponding 95 % confidence interval is calculated,
and a paired t test is performed. A graphical display is
used to examine the distribution of the data; in case of
marked skewness or other non-conformity to test assump-
tions, the appropriate non-parametric tests are employed
as a sensitivity analysis.
For study question 2, mean tremor at the end of the
crossover period with PSA-DBS and VIM-DBS, respect-
ively, is computed, with 95 % confidence intervals. A re-
peated measures analysis of variance, allowing for a
period effect, is performed to quantify and test for a dif-
ference in mean tremor score between PSA and VIM in
the crossover design. The mean difference between PSA
and VIM with 95 % confidence interval is calculated
from the model. Similarly for secondary outcomes, mean
values under the two treatments are computed and com-
pared using repeated measures analysis of variance.
All analyses are based on the intention-to-treat principle.
Study question 1 is analyzed using the full analysis set in-
cluding all randomized patients who begin PSA stimulation
in the crossover period and who have a post-PSA stimula-
tion evaluation. Study question 2 is analyzed using the
crossover analysis set including all patients in the full ana-
lysis set who also begin VIM stimulation in the appropriate
crossover period and who have a post-VIM stimulation
evaluation. Additional analyses are performed on the per
protocol set including all randomized patients who are eli-
gible for the study according to all main inclusion/exclusion
criteria and who are stimulated according to protocol in
both crossover periods. Sensitivity analyses drop the re-
quirement for post-stimulation examination data and
instead impute any missing values (see below). The
safety set includes all patients (randomized or not) who
begin stimulation in any area (PSA, VIM, or ICL).
Since all patients included into the trial receive DBS
electrodes, they are followed closely by our center for
many years after the implantation. After completion of
the study protocol, patients are seen at least every
6 months in our outpatient clinic. A careful evaluation
and (if appropriate) adjustment of stimulation parame-
ters usually leads to improvement of tremor suppression
and quality of life. In the rare case of loss to follow-up,
noncompliance, or revocation of study participation, the
patient will be excluded from the per protocol analysis.
Handling of missing data
If only one component of a multiple component score
(such as TRS part A, B, or C; QUEST part A to E; or
SF-36 item groups 3 to 11) is incomplete, the missing
item value(s) will be imputed using the most frequent
(mode) response to this item in the entire group at the
corresponding time point.
If a value measured after DBS is completely missing,
the patient will be excluded from the main analysis of
the corresponding endpoint. However, in order to guard
against bias, a sensitivity analysis is performed rein-
cluding these patients and using multiple imputation
methods.
Randomization
Block randomization with random varying block length
is employed in order to generate balanced allocations
over the two crossover groups. Numbered, sealed enve-
lopes are produced, and these are opened sequentially
for each enrolled patient. Due to the small sample size
and since a crossover design is employed, it is not con-
sidered useful to stratify the randomization.
Implantation procedure
The general surgical procedure has been published in
detail before. Patients are operated under local anesthesia
with sedation (remifentanil and propofol).
In summary, after fixation of the stereotactic frame
(CRW Stereotactic System, Integra Neurosciences, or
Riechert-Mundinger frame), planning is performed on
fused stereotactic CT/MRI images, with the Framelink
(Medtronic Inc.) or STP 3.5 (Leibinger) planning station.
The trajectory is planned so that both VIM and PSA
can be stimulated, with one electrode contact on the
AC-PC level. Macrostimulation is performed in all pa-
tients. Microrecording is selected in a number of patients
based on the surgeon’s preference. Implanted electrodes
are quadripolar electrodes from Medtronic Inc. (model
3387 or 3389) or octopolar electrodes from Boston Scien-
tific (model 616010).
Finally, the pulse generator (Activa PC, model 37601;
Activa RC, model 37612, Medtronic, USA or Vercise,
Boston Scientific, USA) is implanted subcutaneously in
the infraclavicular or lateral abdominal region under
general anesthesia.
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DBS programming
Directly after implantation and until 7MFU the activated
electrode contact is determined by the study protocol
(ICL, PSA, VIM or ICL, VIM, PSA), but the parameters
can be freely chosen in terms of amplitude, frequency,
and pulse width. However, all patients must be stimu-
lated with constant current (mA), with a positive case
and a single active cathode. In the crossover phase, at
each programming visit, a monopolar review from 0 to
5 mA in 0.5-mA increments is performed. The ampli-
tude with the best effect and fewest side effects is chosen
for the final setting and is usually further adapted by the
investigator during the programming visit before dis-
charge. In general, a monopolar configuration with 60 μs
and 130 Hz is chosen initially. In case a patient does not
present a sufficient effect, the frequency and pulse width
can be additionally modulated to improve the outcome.
If stimulation on a certain contact does not lead to a
sufficient effect or intolerable side effects occur, and thus
a change of the electrode contact or electrode configur-
ation is inevitable, the corresponding crossover phase
cannot be continued for ethical reasons. In this case the
EV of the respective crossover phase must be performed
immediately. After the end of the crossover phase, at
7MFU, the activated contact can be freely chosen.
Blinding
During the crossover phase the study is performed in a
double-blinded design. To ensure that neither the pa-
tient nor the physician is aware of the stimulation site
(PSA or VIM), during the blinded crossover phase, each
patient is seen by a blinded and an unblinded investigator
(the latter usually being a study nurse). The unblinded
study nurse performs all DBS programming during that
phase. The physician decides according to clinical impres-
sion whether the stimulation parameters need to be modi-
fied (e.g., increase or decrease of amplitude or modulation
of pulse width or frequency). The stimulation parameters
and especially the activated contact (VIM or PSA) are doc-
umented in a separate file not accessible by the blinded
physician. The blinded physician will be unblinded after
all case report form (CRF) documentation of the crossover
phase has been completed.
For the preoperative versus postoperative comparison
of tremor suppression, all patients are videotaped and
analyzed by an independent rater. The patients wear sur-
gical caps before and after implantation, so that the rater
cannot deduce the time point of data collection (i.e., pre-
operative versus postoperative) from, e.g., scars or short
hair after implantation.
Withdrawal from the study
In case of unexpected harm to the patient, insufficient
compliance, or withdrawal of informed consent, a patient
will promptly be excluded from further study treatment.
In any case of premature withdrawal during the trial, the
reasons for withdrawal must be documented in the CRF.
The withdrawn subject will undergo a final examination
(final visit) which must be documented.
Safety
Implantation of electrodes in the PSA has so far not
been associated with a higher risk for complications in
these patients.
Adverse events (AEs)/serious adverse events (SAEs)
are documented at the scheduled and unscheduled clin-
ical visits. All incidents are reported to the regulatory au-
thority. All safety-relevant events are promptly reported to
the ethics committee and the safety monitor (Prof. J. Voges,
Department of Stereotactic Neurosurgery, University of
Magdeburg, Germany).
Quality assurance/monitoring
Monitoring is performed by the Clinical Trials Centre
Cologne (CTC Cologne). Monitors inspect the study
center regularly to ensure implementation of the study
protocol and high quality of documentation. An initi-
ation visit, four regular visits, and a close-out visit are
performed. Original source documents are reviewed for
verification of data in the CRF. For each patient the
presence of written consent is checked and the inclusion
and exclusion criteria are controlled.
Documentation
All data relevant to the trial are documented soon after
measurement by the responsible investigator in the CRF
supplied, with signature.
Data management
IT infrastructure and data management are provided by
the CTC Cologne. The data management system is based
on commercial trial software and includes a database. The
trial database was developed and validated before data
entry based on standard operating procedures at the CTC
Cologne. All changes made to the data are documented in
an audit trail. The trial software has a user and role con-
cept that can be adjusted on a trial-specific basis. The
database is integrated into a general IT infrastructure and
safety concept with a firewall and backup system. The data
are backed up daily. After completion and cleaning of
data, the database is locked and the data exported for stat-
istical analysis.
The arrival of CRFs at the CTC Cologne is docu-
mented and the CRFs are checked for completeness.
Data entry staff members enter the data into a validated
trial database using independent double data entry, and
the data entered are compared and reconciled afterwards.
Plausibility checks are also conducted in the database.
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Discrepancies and implausible values are clarified in
writing between the data manager and the trial site.
The trial site has to answer these queries without un-
reasonable delay. Further details will be specified in the
data management manual.
Data protection
The provisions of data protection legislation will be ob-
served. It is assured by the sponsor that all investigational
materials and data will be pseudonymized in accordance
with data protection legislation before scientific processing.
Trial subjects will be informed that their pseudonymized
data will be passed on in accordance with provisions for
documentation and notification pursuant to sections 12
and 13 of the Good Clinical Practice (GCP) regulations to
the recipients described there. Subjects who do not agree
that the information may be passed on in this way will not
be enrolled into the trial.
Discussion
This study investigates the effects and side effects of
deep brain stimulation of the PSA and — with the help
of the randomized crossover — contrasts the outcome
with that of VIM stimulation. Although this mono-
centric study will primarily serve as a pilot study for a
larger, multicentric trial, we expect direct findings to im-
prove treatment of future patients with ET, e.g., through
a better understanding of the side effect profiles of the
two target areas.
So far, results on PSA versus VIM stimulation are con-
flicting, and it is unclear whether the higher efficacy of
PSA stimulation compared to VIM stimulation is sus-
tained in the clinical setting when the amount of current
and the amount and severity of stimulation-induced side
effects might vary between the two target areas. Theoret-
ically, the higher efficacy of PSA stimulation over VIM
stimulation might potentially be neutralized by the use
of stronger current in the VIM group or more frequent
side effects in the PSA group, the latter limiting accept-
able program settings in that target area.
Therefore, first, this study was designed such that pa-
tients are stimulated with constant current and not con-
stant voltage to facilitate direct comparison of the amount
of current (independent of the impedance of the electrode
contacts) applied to the target area in both groups. Sec-
ondly, our study strongly focuses on stimulation-induced
side effects in both target areas. If our study detects a
lower rate of side effects in one of the two groups, this
could relativize the result on tremor suppression. In fact,
it might be the therapeutic window, which comprises ef-
fect and side effect, and not the mere amount of tremor
suppression that is crucial for preference of one or the
other target area. Thirdly, the required sample size for
demonstrating non-inferiority of PSA-DBS compared to
VIM-DBS is the same as that calculated to demonstrate
superiority if the non-inferiority margin is set at a differ-
ence of 9 Essential Tremor Rating Scale (ETRS) points in
favor of VIM-DBS (with the same values of standard devi-
ation, alpha, and power and assuming a true difference of
zero). Therefore, our study has an acceptable power to
show approximate non-inferiority for the case that tremor
suppression is similar with both treatments, but side ef-
fects are reduced under PSA stimulation.
The main strength of this study is the randomization
of the patients in the double-blinded crossover phase.
Potential limitations of the study are the relatively small
sample size and a possible period effect of the crossover.
The results of this pilot study need to be confirmed in a
larger trial. Like other trials investigating the effects of
DBS for the treatment of ET, there are some other
DBS-specific methodological limitations. It is commonly
accepted that, due to the direct and strong effect of VIM-
DBS in ET patients, a truly blinded analysis of the pre-
operative to the postoperative state is probably impossible
[2]. To circumvent this bias, we have designed a double-
blinded analysis for the crossover trial comparing VIM
and PSA, videotaping the preoperative and postoperative
tremor scores for blinded analysis by an independent rater.
Assuming that VIM and PSA stimulations do not differ
strongly and predictably in effectiveness or side effects,
the randomized crossover comparison is thus effectively
blinded.
Trial status
At the time of submission, recruitment has not been
completed.
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